MMM heads into its Monday Q2 earnings report with the most consequential analyst move in months landing just days before the bell — and short sellers still absent from the other side.
JP Morgan upgraded the stock to Overweight on Thursday, lifting its target to $180, a notable shift in stance from a bellwether firm two trading sessions before results. That upgrade lands against a divided backdrop: RBC Capital simultaneously trimmed its target to $123 while holding its Underperform rating, a gap of $57 between the two most recent target revisions that captures the disagreement unusually starkly. Bulls point to four consecutive quarters of consumer growth, adjusted operating margins running at 24.4%, and guidance calling for a further 100 basis points of segment-level margin expansion in 2026. Bears counter with a consumer segment shortfall, slowing Chinese industrial output, and residual PFAS litigation risk. The stock's forward earnings yield has drifted modestly lower over the past week, and the PE ratio at 17.7x leaves limited room for disappointment if guidance disappoints.
Short positioning provides no meaningful headwind or tailwind. Bears covered hard on July 10 ahead of the rescheduled print and have not rebuilt — short interest now runs at just 1.92% of the free float, with the ORTEX short score easing to 31.5. Borrow conditions remain essentially frictionless: cost to borrow is running at 0.48% and availability is unconstrained, with over 500 million shares in the lending pool seeing virtually no demand. The options market tells a similarly calm story — the put/call ratio at 0.76 is slightly below its 20-day average of 0.81, a mild lean toward calls rather than hedges, and a long way from the defensive PCR readings above 1.3 that prevailed in early June.
The most recent comparable earnings print — Q1 results in April — produced a 3.7% one-day decline followed by a further drift lower over five sessions. The two most recent reports each resolved to the downside on day one, with only the May print, tied to a different period, generating a positive reaction. Monday's release is therefore less a test of whether 3M is growing and more a question of whether JP Morgan's freshly issued upgrade — and the margin expansion narrative it rests on — holds up once management speaks to the second half.
See the live data behind this article on ORTEX.
Open MMM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
